Details

Autor(en) / Beteiligte

• Ding, M J
• Jie, X X
• Li, H J
• Xu, Z Y
• Nian, L
• Qi, K M
• Yan, Z L
• Zhu, F
• Cao, J
• Zhang, H X
• Xu, K L
• Cheng, H
• Li, Z Y

Titel

Impact of autologous hematopoietic stem cell transplantation on the efficacy of CAR-T treatment of relapsed/refractory multiple myeloma

Ist Teil von

• Chung-hua nei kʿo tsa chih, 2024-06, Vol.63 (6), p.587

Ort / Verlag

China

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• To evaluate the effect of autologous hematopoietic stem cell transplantation (ASCT) on the treatment of relapsed/refractory multiple myeloma (RRMM) with chimeric antigen receptor T cell (CAR-T) therapy. A retrospective cohort study. The clinical data of 168 patients with RRMM who underwent CAR-T therapy at the Department of Hematology, Xuzhou Medical University Hospital from 3 January 2020 to 13 September 2022 were analyzed. Patients were classified into a transplantation group (TG; =47) and non-transplantation group (NTG; =121) based on whether or not they had undergone ASCT previously. The objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and the levels of CD3, CD4, CD8, CD19, CD56 and natural killer (NK) cells before CAR-T infusion were analyzed by test, Kaplan-Meier method and independent sample -test. Among 168 patients with RRMM, 98 (58.3%) were male. The median age of onset was 57 (range 30-70) years. After CAR-T therapy, the ORR of patients was 89.3% (92/103) in the